NASDAQ:CHRS Coherus Oncology Q3 2026 Earnings Date & Estimates $1.07 0.00 (0.00%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.09 +0.02 (+1.87%) As of 10/9/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Coherus Oncology is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 5:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeAfter Market ClosesConference Call5:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Coherus Oncology in Q3 2026Coherus Oncology is expected to post earnings of -$0.21 per share on revenue of $15.98 million. In the same quarter a year earlier Coherus Oncology reported -$0.33 per share on revenue of $11.57 million. Coherus Oncology last reported on August 5, 2026, posting -$0.19 per share and beating the -$0.25 consensus estimate. Coherus Oncology has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.21Expected Revenue$15.98 millionPrior-Year EPS-$0.33Prior-Year Revenue$11.57 millionExpected Revenue Growth+38.1%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.19 (Beat by +$0.06)Last Quarter Revenue$14.31 millionEPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Coherus Oncology Q3 2026 Earnings FAQ When does Coherus Oncology report Q3 2026 earnings? Coherus Oncology (NASDAQ:CHRS) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. What time is Coherus Oncology's Q3 2026 earnings call? Coherus Oncology's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Coherus Oncology? Analysts expect Coherus Oncology to post earnings of -$0.21 per share for Q3 2026. How much revenue is Coherus Oncology expected to report? The consensus revenue estimate for Coherus Oncology is $15.98 million for Q3 2026. Coherus Oncology Earnings HeadlinesCoherus Oncology Starts Process to Sell Remaining Biosimilar AssetsSeptember 24, 2026 | finance.yahoo.comCoherus Oncology Initiates Process to Sell Remaining Legacy Biosimilars Assets, Announces CVR DetailsSeptember 23, 2026 | quiverquant.comQNo. 1 stock to cash in on the death of iPhoneAnalyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now.October 10 at 1:00 AM | Stansberry Research (Ad)Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar AssetsSeptember 23, 2026 | globenewswire.comCoherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comCoherus to Participate in Upcoming Investor ConferencesAugust 31, 2026 | globenewswire.comSee More Coherus Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Coherus Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coherus Oncology and other key companies, straight to your email. Email Address About Coherus OncologyCoherus Oncology (NASDAQ:CHRS), formerly known as Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing medicines for cancer care. The company applies biologic and biosimilar development expertise to oncology and supportive-care products, with an emphasis on treatments that address significant unmet medical needs. Its portfolio includes UDENYCA (pegfilgrastim-cbqv), a pegfilgrastim biosimilar used to reduce the risk of infection associated with chemotherapy-induced febrile neutropenia. Coherus also markets LOQTORZI (toripalimab-tpzi), an immunotherapy approved in the United States for certain patients with nasopharyngeal carcinoma. UDENYCA is available in multiple delivery formats, including an on-body injector presentation. Coherus was founded in 2010 and has historically developed and commercialized biosimilar medicines in the United States, including products in oncology and immunology. The company has also worked with international partners, including Junshi Biosciences, to bring therapies to additional markets. Coherus Oncology is led by Denny Lanfear, who serves as president and chief executive officer.View Coherus Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
